1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1.2.2 ChemOthersapy 1.2.3 Targeted Drug Therapy 1.2.4 Radiation Therapy 1.3 Market by Application 1.3.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 1.6 Years Considered 2 Global Growth Trends 2.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Perspective (2018-2029) 2.2 Glioblastoma Multiforme (GBM) Therapeutics Growth Trends by Region 2.2.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Glioblastoma Multiforme (GBM) Therapeutics Historic Market Size by Region (2018-2023) 2.2.3 Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Region (2024-2029) 2.3 Glioblastoma Multiforme (GBM) Therapeutics Market Dynamics 2.3.1 Glioblastoma Multiforme (GBM) Therapeutics Industry Trends 2.3.2 Glioblastoma Multiforme (GBM) Therapeutics Market Drivers 2.3.3 Glioblastoma Multiforme (GBM) Therapeutics Market Challenges 2.3.4 Glioblastoma Multiforme (GBM) Therapeutics Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Revenue 3.1.1 Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Revenue (2018-2023) 3.1.2 Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Players (2018-2023) 3.2 Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Glioblastoma Multiforme (GBM) Therapeutics Revenue 3.4 Global Glioblastoma Multiforme (GBM) Therapeutics Market Concentration Ratio 3.4.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Glioblastoma Multiforme (GBM) Therapeutics Revenue in 2022 3.5 Glioblastoma Multiforme (GBM) Therapeutics Key Players Head office and Area Served 3.6 Key Players Glioblastoma Multiforme (GBM) Therapeutics Product Solution and Service 3.7 Date of Enter into Glioblastoma Multiforme (GBM) Therapeutics Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Glioblastoma Multiforme (GBM) Therapeutics Breakdown Data by Type 4.1 Global Glioblastoma Multiforme (GBM) Therapeutics Historic Market Size by Type (2018-2023) 4.2 Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Type (2024-2029) 5 Glioblastoma Multiforme (GBM) Therapeutics Breakdown Data by Application 5.1 Global Glioblastoma Multiforme (GBM) Therapeutics Historic Market Size by Application (2018-2023) 5.2 Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size (2018-2029) 6.2 North America Glioblastoma Multiforme (GBM) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 6.3 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2018-2023) 6.4 North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2024-2029) 6.5 United States 6.6 Canada 7 Europe 7.1 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size (2018-2029) 7.2 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 7.3 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2018-2023) 7.4 Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2024-2029) 7.5 Germany 7.6 France 7.7 U.K. 7.8 Italy 7.9 Russia 7.10 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size (2018-2029) 8.2 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029 8.3 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (2018-2023) 8.4 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (2024-2029) 8.5 China 8.6 Japan 8.7 South Korea 8.8 Southeast Asia 8.9 India 8.10 Australia 9 Latin America 9.1 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size (2018-2029) 9.2 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 9.3 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2018-2023) 9.4 Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2024-2029) 9.5 Mexico 9.6 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size (2018-2029) 10.2 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 10.3 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2018-2023) 10.4 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2024-2029) 10.5 Turkey 10.6 Saudi Arabia 10.7 UAE 11 Key Players Profiles 11.1 Merck 11.1.1 Merck Company Detail 11.1.2 Merck Business Overview 11.1.3 Merck Glioblastoma Multiforme (GBM) Therapeutics Introduction 11.1.4 Merck Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) 11.1.5 Merck Recent Development 11.2 Roche 11.2.1 Roche Company Detail 11.2.2 Roche Business Overview 11.2.3 Roche Glioblastoma Multiforme (GBM) Therapeutics Introduction 11.2.4 Roche Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) 11.2.5 Roche Recent Development 11.3 Arbor Pharmaceuticals 11.3.1 Arbor Pharmaceuticals Company Detail 11.3.2 Arbor Pharmaceuticals Business Overview 11.3.3 Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Introduction 11.3.4 Arbor Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) 11.3.5 Arbor Pharmaceuticals Recent Development 11.4 Pfizer 11.4.1 Pfizer Company Detail 11.4.2 Pfizer Business Overview 11.4.3 Pfizer Glioblastoma Multiforme (GBM) Therapeutics Introduction 11.4.4 Pfizer Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) 11.4.5 Pfizer Recent Development 11.5 AbbVie 11.5.1 AbbVie Company Detail 11.5.2 AbbVie Business Overview 11.5.3 AbbVie Glioblastoma Multiforme (GBM) Therapeutics Introduction 11.5.4 AbbVie Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) 11.5.5 AbbVie Recent Development 11.6 Amgen 11.6.1 Amgen Company Detail 11.6.2 Amgen Business Overview 11.6.3 Amgen Glioblastoma Multiforme (GBM) Therapeutics Introduction 11.6.4 Amgen Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) 11.6.5 Amgen Recent Development 11.7 Bristol-Myers Squibb 11.7.1 Bristol-Myers Squibb Company Detail 11.7.2 Bristol-Myers Squibb Business Overview 11.7.3 Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Introduction 11.7.4 Bristol-Myers Squibb Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) 11.7.5 Bristol-Myers Squibb Recent Development 11.8 Sun Pharmaceuticals 11.8.1 Sun Pharmaceuticals Company Detail 11.8.2 Sun Pharmaceuticals Business Overview 11.8.3 Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Introduction 11.8.4 Sun Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) 11.8.5 Sun Pharmaceuticals Recent Development 11.9 Teva Pharmaceutical 11.9.1 Teva Pharmaceutical Company Detail 11.9.2 Teva Pharmaceutical Business Overview 11.9.3 Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Introduction 11.9.4 Teva Pharmaceutical Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) 11.9.5 Teva Pharmaceutical Recent Development 11.10 Emcure Pharmaceuticals 11.10.1 Emcure Pharmaceuticals Company Detail 11.10.2 Emcure Pharmaceuticals Business Overview 11.10.3 Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Introduction 11.10.4 Emcure Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) 11.10.5 Emcure Pharmaceuticals Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029 Table 2. Key Players of ChemOthersapy Table 3. Key Players of Targeted Drug Therapy Table 4. Key Players of Radiation Therapy Table 5. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029 Table 6. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 7. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (2018-2023) & (US$ Million) Table 8. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Region (2018-2023) Table 9. Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million) Table 10. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Region (2024-2029) Table 11. Glioblastoma Multiforme (GBM) Therapeutics Market Trends Table 12. Glioblastoma Multiforme (GBM) Therapeutics Market Drivers Table 13. Glioblastoma Multiforme (GBM) Therapeutics Market Challenges Table 14. Glioblastoma Multiforme (GBM) Therapeutics Market Restraints Table 15. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue by Players (2018-2023) & (US$ Million) Table 16. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Players (2018-2023) Table 17. Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glioblastoma Multiforme (GBM) Therapeutics as of 2022) Table 18. Ranking of Global Top Glioblastoma Multiforme (GBM) Therapeutics Companies by Revenue (US$ Million) in 2022 Table 19. Global 5 Largest Players Market Share by Glioblastoma Multiforme (GBM) Therapeutics Revenue (CR5 and HHI) & (2018-2023) Table 20. Key Players Headquarters and Area Served Table 21. Key Players Glioblastoma Multiforme (GBM) Therapeutics Product Solution and Service Table 22. Date of Enter into Glioblastoma Multiforme (GBM) Therapeutics Market Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size by Type (2018-2023) & (US$ Million) Table 25. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Type (2018-2023) Table 26. Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million) Table 27. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Type (2024-2029) Table 28. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size by Application (2018-2023) & (US$ Million) Table 29. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Application (2018-2023) Table 30. Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million) Table 31. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share by Application (2024-2029) Table 32. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 33. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2018-2023) & (US$ Million) Table 34. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2024-2029) & (US$ Million) Table 35. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 36. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2018-2023) & (US$ Million) Table 37. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2024-2029) & (US$ Million) Table 38. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029 Table 39. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (2018-2023) & (US$ Million) Table 40. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size by Region (2024-2029) & (US$ Million) Table 41. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 42. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2018-2023) & (US$ Million) Table 43. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2024-2029) & (US$ Million) Table 44. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 45. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2018-2023) & (US$ Million) Table 46. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size by Country (2024-2029) & (US$ Million) Table 47. Merck Company Detail Table 48. Merck Business Overview Table 49. Merck Glioblastoma Multiforme (GBM) Therapeutics Product Table 50. Merck Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) & (US$ Million) Table 51. Merck Recent Development Table 52. Roche Company Detail Table 53. Roche Business Overview Table 54. Roche Glioblastoma Multiforme (GBM) Therapeutics Product Table 55. Roche Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) & (US$ Million) Table 56. Roche Recent Development Table 57. Arbor Pharmaceuticals Company Detail Table 58. Arbor Pharmaceuticals Business Overview Table 59. Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Product Table 60. Arbor Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) & (US$ Million) Table 61. Arbor Pharmaceuticals Recent Development Table 62. Pfizer Company Detail Table 63. Pfizer Business Overview Table 64. Pfizer Glioblastoma Multiforme (GBM) Therapeutics Product Table 65. Pfizer Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) & (US$ Million) Table 66. Pfizer Recent Development Table 67. AbbVie Company Detail Table 68. AbbVie Business Overview Table 69. AbbVie Glioblastoma Multiforme (GBM) Therapeutics Product Table 70. AbbVie Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) & (US$ Million) Table 71. AbbVie Recent Development Table 72. Amgen Company Detail Table 73. Amgen Business Overview Table 74. Amgen Glioblastoma Multiforme (GBM) Therapeutics Product Table 75. Amgen Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) & (US$ Million) Table 76. Amgen Recent Development Table 77. Bristol-Myers Squibb Company Detail Table 78. Bristol-Myers Squibb Business Overview Table 79. Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Product Table 80. Bristol-Myers Squibb Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) & (US$ Million) Table 81. Bristol-Myers Squibb Recent Development Table 82. Sun Pharmaceuticals Company Detail Table 83. Sun Pharmaceuticals Business Overview Table 84. Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Product Table 85. Sun Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) & (US$ Million) Table 86. Sun Pharmaceuticals Recent Development Table 87. Teva Pharmaceutical Company Detail Table 88. Teva Pharmaceutical Business Overview Table 89. Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Product Table 90. Teva Pharmaceutical Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) & (US$ Million) Table 91. Teva Pharmaceutical Recent Development Table 92. Emcure Pharmaceuticals Company Detail Table 93. Emcure Pharmaceuticals Business Overview Table 94. Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Product Table 95. Emcure Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) & (US$ Million) Table 96. Emcure Pharmaceuticals Recent Development Table 97. Research Programs/Design for This Report Table 98. Key Data Information from Secondary Sources Table 99. Key Data Information from Primary Sources List of Figures Figure 1. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million) Figure 2. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Type: 2022 VS 2029 Figure 3. ChemOthersapy Features Figure 4. Targeted Drug Therapy Features Figure 5. Radiation Therapy Features Figure 6. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Comparison by Application (2023-2029) & (US$ Million) Figure 7. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Application: 2022 VS 2029 Figure 8. Hospitals Case Studies Figure 9. Clinics Case Studies Figure 10. Others Case Studies Figure 11. Glioblastoma Multiforme (GBM) Therapeutics Report Years Considered Figure 12. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029 Figure 13. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029 Figure 14. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Region: 2022 VS 2029 Figure 15. Global Glioblastoma Multiforme (GBM) Therapeutics Market Share by Players in 2022 Figure 16. Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glioblastoma Multiforme (GBM) Therapeutics as of 2022) Figure 17. The Top 10 and 5 Players Market Share by Glioblastoma Multiforme (GBM) Therapeutics Revenue in 2022 Figure 18. North America Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 19. North America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Country (2018-2029) Figure 20. United States Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 21. Canada Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 22. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 23. Europe Glioblastoma Multiforme (GBM) Therapeutics Market Share by Country (2018-2029) Figure 24. Germany Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 25. France Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 26. U.K. Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 27. Italy Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 28. Russia Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 29. Nordic Countries Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 30. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 31. Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics Market Share by Region (2018-2029) Figure 32. China Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 33. Japan Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 34. South Korea Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 35. Southeast Asia Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 36. India Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 37. Australia Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 38. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 39. Latin America Glioblastoma Multiforme (GBM) Therapeutics Market Share by Country (2018-2029) Figure 40. Mexico Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 41. Brazil Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 42. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 43. Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Market Share by Country (2018-2029) Figure 44. Turkey Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 45. Saudi Arabia Glioblastoma Multiforme (GBM) Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 46. Merck Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) Figure 47. Roche Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) Figure 48. Arbor Pharmaceuticals Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) Figure 49. Pfizer Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) Figure 50. AbbVie Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) Figure 51. Amgen Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) Figure 53. Sun Pharmaceuticals Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) Figure 54. Teva Pharmaceutical Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) Figure 55. Emcure Pharmaceuticals Revenue Growth Rate in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023) Figure 56. Bottom-up and Top-down Approaches for This Report Figure 57. Data Triangulation Figure 58. Key Executives Interviewed

Merck Roche Arbor Pharmaceuticals Pfizer AbbVie Amgen Bristol-Myers Squibb Sun Pharmaceuticals Teva Pharmaceutical Emcure Pharmaceuticals